Table 3 Phagocytosis checkpoint characteristics in tumor immune microenvironment.
Signaling pathway | RT-associated pre-clinical study | Other functions | Radiotherapy efficacy (Activated signaling) | Prognostic significance (Activated signaling) | |
|---|---|---|---|---|---|
“Don’t eat me” signals | CD47-SIRPα | √ (Identified) | Radioresisatnce [58] | Negative [48] | |
PD-L1-PD-1 | √ | T cell-mediated tumor adaptive immune [18] | Radioresistance [85] | Negative [83] | |
MHC-1-LIRB1 | √ | Processing and presenting tumor antigen [94] | Sensitivity to radiotherapy [186] | ||
CD24-Siglec10 | √ | Cancer stem cell marker [103] | Radioresistance [188] | Negative [189] | |
α2–6-linked sialic acid -CD22 | / (Not identified) | Inhibiting B-cell receptor signaling [108] | / | Negative [190] | |
Fc-FcγR IIB | / | / | / | ||
SLAMF3/SLAMF4 | / | CD8+ T cells exhaustion [192] | / | ||
GD-2-Siglec7 | / | Inhibiting CD8+ T cells [194] | / | Negative [113] | |
“Eat me” signals | CRT-LRP1 | √ | Activating DCs [195] | Sensitivity to radiotherapy [124] | |
PS-associated axis | √ | Promoting immune suppression [198] | Radioresistance [133] | Negative [199] | |
SLAMF7-SLAMF7 | / | Activating CD8+ T cells [200] | / | Positive [201] | |
Fc-FcγRs | / | / | / | ||
